Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19033449,AUC,"AUC values were significantly higher for (-)-3S,5R-FV than for (+)-3R,5S-FV (358.20 vs 279.68 ng.h/mL) and for S-LER compared with R-LER (13.90 vs 11.88 ng.h/mL).",Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],358.20,5369,DB01095,Fluvastatin
,19033449,AUC,"AUC values were significantly higher for (-)-3S,5R-FV than for (+)-3R,5S-FV (358.20 vs 279.68 ng.h/mL) and for S-LER compared with R-LER (13.90 vs 11.88 ng.h/mL).",Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],279.68,5370,DB01095,Fluvastatin
,19033449,AUC,"AUC values were significantly higher for (-)-3S,5R-FV than for (+)-3R,5S-FV (358.20 vs 279.68 ng.h/mL) and for S-LER compared with R-LER (13.90 vs 11.88 ng.h/mL).",Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],13.90,5371,DB01095,Fluvastatin
,19033449,AUC,"AUC values were significantly higher for (-)-3S,5R-FV than for (+)-3R,5S-FV (358.20 vs 279.68 ng.h/mL) and for S-LER compared with R-LER (13.90 vs 11.88 ng.h/mL).",Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],11.88,5372,DB01095,Fluvastatin
,19033449,AUC,"The pharmacokinetic parameters of FV were not enantioselective when combined with LER (AUC: (-)-3S,5R-FV: 325.21; (+)-3R,5S-FV: 316.44 ng.h/mL).",Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],325.21,5373,DB01095,Fluvastatin
,19033449,AUC,"The pharmacokinetic parameters of FV were not enantioselective when combined with LER (AUC: (-)-3S,5R-FV: 325.21; (+)-3R,5S-FV: 316.44 ng.h/mL).",Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],316.44,5374,DB01095,Fluvastatin
,19033449,AUC,There was a significant reduction in S-LER (8.06 vs 13.90 ng.h/mL) and R-LER (6.76 vs 11.88 ng.h/mL) AUC values when FV was coadministered.,Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033449/),[h·ng] / [ml],6.76,5375,DB01095,Fluvastatin
,12548150,flow rate,The mobile phase consisted of an aqueous solution containing 20 mmol/L dibasic sodium dihydrogen phosphate with 1 mmol/L sodium lauryl sulfate adjusted to pH 7 with phosphoric acid and acetonitrile (70:30 v/v) delivered at a flow rate of 1.0 mL/min.,Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548150/),[ml] / [min],1.0,10307,DB01095,Fluvastatin
,12548150,retention times,"Under these conditions, the retention times for FV and IS were 8.8 and 10.6 minutes, respectively.",Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548150/),min,8.8,10308,DB01095,Fluvastatin
,12548150,retention times,"Under these conditions, the retention times for FV and IS were 8.8 and 10.6 minutes, respectively.",Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548150/),min,10.6,10309,DB01095,Fluvastatin
,12548150,recovery,The recovery ranged from 88% to 96%.,Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548150/),%,88,10310,DB01095,Fluvastatin
,12548150,recovery,The recovery ranged from 88% to 96%.,Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548150/),%,96,10311,DB01095,Fluvastatin
,22811596,C(max),"For fluvastatin ER tablet 80 mg QD, C(max) was 61.0 ± 39.0 and 63.9 ± 29.7 ng/mL, and AUC(0-24 h) was 242 ± 156 and 253 ± 91.1 ng·h/mL on day 1 and 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),[ng] / [ml],61.0,13521,DB01095,Fluvastatin
,22811596,C(max),"For fluvastatin ER tablet 80 mg QD, C(max) was 61.0 ± 39.0 and 63.9 ± 29.7 ng/mL, and AUC(0-24 h) was 242 ± 156 and 253 ± 91.1 ng·h/mL on day 1 and 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),[ng] / [ml],63.9,13522,DB01095,Fluvastatin
,22811596,AUC(0-24 h),"For fluvastatin ER tablet 80 mg QD, C(max) was 61.0 ± 39.0 and 63.9 ± 29.7 ng/mL, and AUC(0-24 h) was 242 ± 156 and 253 ± 91.1 ng·h/mL on day 1 and 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),[h·ng] / [ml],242,13523,DB01095,Fluvastatin
,22811596,AUC(0-24 h),"For fluvastatin ER tablet 80 mg QD, C(max) was 61.0 ± 39.0 and 63.9 ± 29.7 ng/mL, and AUC(0-24 h) was 242 ± 156 and 253 ± 91.1 ng·h/mL on day 1 and 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),[h·ng] / [ml],253,13524,DB01095,Fluvastatin
,22811596,C(max),"For fluvastatin IR capsule 40 mg BID, C(max) was 283 ± 271 and 382 ± 255 ng/mL, and AUC(0-24 h) was 720 ± 776 and 917 ± 994 ng·h/mL on day 1 and day 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),[ng] / [ml],283,13525,DB01095,Fluvastatin
,22811596,C(max),"For fluvastatin IR capsule 40 mg BID, C(max) was 283 ± 271 and 382 ± 255 ng/mL, and AUC(0-24 h) was 720 ± 776 and 917 ± 994 ng·h/mL on day 1 and day 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),[ng] / [ml],382,13526,DB01095,Fluvastatin
,22811596,AUC(0-24 h),"For fluvastatin IR capsule 40 mg BID, C(max) was 283 ± 271 and 382 ± 255 ng/mL, and AUC(0-24 h) was 720 ± 776 and 917 ± 994 ng·h/mL on day 1 and day 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),[h·ng] / [ml],720,13527,DB01095,Fluvastatin
,22811596,AUC(0-24 h),"For fluvastatin IR capsule 40 mg BID, C(max) was 283 ± 271 and 382 ± 255 ng/mL, and AUC(0-24 h) was 720 ± 776 and 917 ± 994 ng·h/mL on day 1 and day 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),[h·ng] / [ml],917,13528,DB01095,Fluvastatin
,22811596,relative bioavailability,"The relative bioavailability of fluvastatin ER tablet 80 mg QD to fluvastatin IR capsule 40 mg BID is (45.3 ± 23.9)% and (43.3 ± 24.1)% on day 1 and day 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),%,45.3,13529,DB01095,Fluvastatin
,22811596,relative bioavailability,"The relative bioavailability of fluvastatin ER tablet 80 mg QD to fluvastatin IR capsule 40 mg BID is (45.3 ± 23.9)% and (43.3 ± 24.1)% on day 1 and day 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),%,43.3,13530,DB01095,Fluvastatin
,22811596,T(max),"T(max) for fluvastatin ER tablet was 2.50 and 2.60 h and for capsule was 0.78 and 0.88 h on day 1 and day 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),h,2.50,13531,DB01095,Fluvastatin
,22811596,T(max),"T(max) for fluvastatin ER tablet was 2.50 and 2.60 h and for capsule was 0.78 and 0.88 h on day 1 and day 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),h,2.60,13532,DB01095,Fluvastatin
,22811596,T(max),"T(max) for fluvastatin ER tablet was 2.50 and 2.60 h and for capsule was 0.78 and 0.88 h on day 1 and day 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),h,0.78,13533,DB01095,Fluvastatin
,22811596,T(max),"T(max) for fluvastatin ER tablet was 2.50 and 2.60 h and for capsule was 0.78 and 0.88 h on day 1 and day 7, respectively.",The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22811596/),h,0.88,13534,DB01095,Fluvastatin
,12489926,maximum plasma concentration (Cmax),"The following differences (p < 0.05) were observed between the control and diabetic groups, respectively: maximum plasma concentration (Cmax) of (-)-(3S,5R), 410.0 (310.0-510.0) versus 532.6 (463.5-601.8) ng x mL(-7); area under the plasma concentration versus time curve (AUC(0-infinity)) for (-)-(3S,5R), 4342A (3,775.7-4,909.0) versus 3025.2 (2,218.9-3,831.5) ng x h x mL(-1); apparent total clearance (Cl/f) of (-)-(3S,5R), 0.6 (0.5-0.7) versus 0.9 (0.6-1.1) L x h(-1) x kg(-1); AUC(0-infinity) for (+)-(3R,5S), 493.5 (376.9-610.1) versus 758.5 (537.1-980.0) ng x h x mL(-1); and Cl/f of (+)-(3R,5S), 5.3 (3.9-6.8) versus 3.5 (2.6-4.4) L x h(-1) x kg(-1).",Stereospecific disposition of fluvastatin in streptozotocin-induced diabetic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489926/),[ng] / [(ml)^7],410.0,14760,DB01095,Fluvastatin
,12489926,maximum plasma concentration (Cmax),"The following differences (p < 0.05) were observed between the control and diabetic groups, respectively: maximum plasma concentration (Cmax) of (-)-(3S,5R), 410.0 (310.0-510.0) versus 532.6 (463.5-601.8) ng x mL(-7); area under the plasma concentration versus time curve (AUC(0-infinity)) for (-)-(3S,5R), 4342A (3,775.7-4,909.0) versus 3025.2 (2,218.9-3,831.5) ng x h x mL(-1); apparent total clearance (Cl/f) of (-)-(3S,5R), 0.6 (0.5-0.7) versus 0.9 (0.6-1.1) L x h(-1) x kg(-1); AUC(0-infinity) for (+)-(3R,5S), 493.5 (376.9-610.1) versus 758.5 (537.1-980.0) ng x h x mL(-1); and Cl/f of (+)-(3R,5S), 5.3 (3.9-6.8) versus 3.5 (2.6-4.4) L x h(-1) x kg(-1).",Stereospecific disposition of fluvastatin in streptozotocin-induced diabetic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489926/),[ng] / [(ml)^7],532.6,14761,DB01095,Fluvastatin
,12489926,area under the plasma concentration versus time curve (AUC(0-infinity)),"The following differences (p < 0.05) were observed between the control and diabetic groups, respectively: maximum plasma concentration (Cmax) of (-)-(3S,5R), 410.0 (310.0-510.0) versus 532.6 (463.5-601.8) ng x mL(-7); area under the plasma concentration versus time curve (AUC(0-infinity)) for (-)-(3S,5R), 4342A (3,775.7-4,909.0) versus 3025.2 (2,218.9-3,831.5) ng x h x mL(-1); apparent total clearance (Cl/f) of (-)-(3S,5R), 0.6 (0.5-0.7) versus 0.9 (0.6-1.1) L x h(-1) x kg(-1); AUC(0-infinity) for (+)-(3R,5S), 493.5 (376.9-610.1) versus 758.5 (537.1-980.0) ng x h x mL(-1); and Cl/f of (+)-(3R,5S), 5.3 (3.9-6.8) versus 3.5 (2.6-4.4) L x h(-1) x kg(-1).",Stereospecific disposition of fluvastatin in streptozotocin-induced diabetic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489926/),[h·ng] / [ml],4342A,14762,DB01095,Fluvastatin
,12489926,area under the plasma concentration versus time curve (AUC(0-infinity)),"The following differences (p < 0.05) were observed between the control and diabetic groups, respectively: maximum plasma concentration (Cmax) of (-)-(3S,5R), 410.0 (310.0-510.0) versus 532.6 (463.5-601.8) ng x mL(-7); area under the plasma concentration versus time curve (AUC(0-infinity)) for (-)-(3S,5R), 4342A (3,775.7-4,909.0) versus 3025.2 (2,218.9-3,831.5) ng x h x mL(-1); apparent total clearance (Cl/f) of (-)-(3S,5R), 0.6 (0.5-0.7) versus 0.9 (0.6-1.1) L x h(-1) x kg(-1); AUC(0-infinity) for (+)-(3R,5S), 493.5 (376.9-610.1) versus 758.5 (537.1-980.0) ng x h x mL(-1); and Cl/f of (+)-(3R,5S), 5.3 (3.9-6.8) versus 3.5 (2.6-4.4) L x h(-1) x kg(-1).",Stereospecific disposition of fluvastatin in streptozotocin-induced diabetic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489926/),[h·ng] / [ml],3025.2,14763,DB01095,Fluvastatin
,12489926,apparent total clearance (Cl/f),"The following differences (p < 0.05) were observed between the control and diabetic groups, respectively: maximum plasma concentration (Cmax) of (-)-(3S,5R), 410.0 (310.0-510.0) versus 532.6 (463.5-601.8) ng x mL(-7); area under the plasma concentration versus time curve (AUC(0-infinity)) for (-)-(3S,5R), 4342A (3,775.7-4,909.0) versus 3025.2 (2,218.9-3,831.5) ng x h x mL(-1); apparent total clearance (Cl/f) of (-)-(3S,5R), 0.6 (0.5-0.7) versus 0.9 (0.6-1.1) L x h(-1) x kg(-1); AUC(0-infinity) for (+)-(3R,5S), 493.5 (376.9-610.1) versus 758.5 (537.1-980.0) ng x h x mL(-1); and Cl/f of (+)-(3R,5S), 5.3 (3.9-6.8) versus 3.5 (2.6-4.4) L x h(-1) x kg(-1).",Stereospecific disposition of fluvastatin in streptozotocin-induced diabetic rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489926/),[l] / [h·kg],0.6,14764,DB01095,Fluvastatin
,12489926,apparent total clearance (Cl/f),"The following differences (p < 0.05) were observed between the control and diabetic groups, respectively: maximum plasma concentration (Cmax) of (-)-(3S,5R), 410.0 (310.0-510.0) versus 532.6 (463.5-601.8) ng x mL(-7); area under the plasma concentration versus time curve (AUC(0-infinity)) for (-)-(3S,5R), 4342A (3,775.7-4,909.0) versus 3025.2 (2,218.9-3,831.5) ng x h x mL(-1); apparent total clearance (Cl/f) of (-)-(3S,5R), 0.6 (0.5-0.7) versus 0.9 (0.6-1.1) L x h(-1) x kg(-1); AUC(0-infinity) for (+)-(3R,5S), 493.5 (376.9-610.1) versus 758.5 (537.1-980.0) ng x h x mL(-1); and Cl/f of (+)-(3R,5S), 5.3 (3.9-6.8) versus 3.5 (2.6-4.4) L x h(-1) x kg(-1).",Stereospecific disposition of fluvastatin in streptozotocin-induced diabetic rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489926/),[l] / [h·kg],0.9,14765,DB01095,Fluvastatin
,12489926,AUC(0-infinity),"The following differences (p < 0.05) were observed between the control and diabetic groups, respectively: maximum plasma concentration (Cmax) of (-)-(3S,5R), 410.0 (310.0-510.0) versus 532.6 (463.5-601.8) ng x mL(-7); area under the plasma concentration versus time curve (AUC(0-infinity)) for (-)-(3S,5R), 4342A (3,775.7-4,909.0) versus 3025.2 (2,218.9-3,831.5) ng x h x mL(-1); apparent total clearance (Cl/f) of (-)-(3S,5R), 0.6 (0.5-0.7) versus 0.9 (0.6-1.1) L x h(-1) x kg(-1); AUC(0-infinity) for (+)-(3R,5S), 493.5 (376.9-610.1) versus 758.5 (537.1-980.0) ng x h x mL(-1); and Cl/f of (+)-(3R,5S), 5.3 (3.9-6.8) versus 3.5 (2.6-4.4) L x h(-1) x kg(-1).",Stereospecific disposition of fluvastatin in streptozotocin-induced diabetic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489926/),,493.5,14766,DB01095,Fluvastatin
,29368187,IC50,"EGCG inhibited diclofenac 4'-hydroxylation and fluvastatin degradation with IC50 of 2.23 and 48.04 μM, respectively.",Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29368187/),μM,2.23,15169,DB01095,Fluvastatin
,29368187,IC50,"EGCG inhibited diclofenac 4'-hydroxylation and fluvastatin degradation with IC50 of 2.23 and 48.04 μM, respectively.",Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29368187/),μM,48.04,15170,DB01095,Fluvastatin
,29701749,total runtime,Polarity switch (negative-positive-negative ionization mode) was performed in a total runtime of 5.0 min.,"Simultaneous determination of rosuvastatin, naringin and naringenin in rat plasma by RRLC-MS/MS and its application to a pharmacokinetic drug interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29701749/),min,5.0,18963,DB01095,Fluvastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),min,30,27657,DB01095,Fluvastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,15,27658,DB01095,Fluvastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,2,27659,DB01095,Fluvastatin
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,15.6,27660,DB01095,Fluvastatin
,23776402,50% inhibition concentration(IC50),Fluvastatin inhibited CYP3A4 activity in a concentration-dependent manner with a 50% inhibition concentration(IC50) of 4.1 µM and P-gp activity.,Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23776402/),μM,4.1,30335,DB01095,Fluvastatin
,26396513,bioavailability,"The limitations include poor solubility and extensive first-pass metabolism, resulting in low (30%) bioavailability and short elimination half-life (1-3 hours).",Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26396513/),%,30,32615,DB01095,Fluvastatin
,26396513,elimination half-life,"The limitations include poor solubility and extensive first-pass metabolism, resulting in low (30%) bioavailability and short elimination half-life (1-3 hours).",Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26396513/),h,1-3,32616,DB01095,Fluvastatin
,7586933,peak concentration (Cmax),"Diclofenac peak concentration (Cmax) increased over time (0.28 [SD, 0.12], 0.38 [0.20], and 0.45 [0.4] mg/L on days 0, 1, and 8, respectively).",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.28,35122,DB01095,Fluvastatin
,7586933,peak concentration (Cmax),"Diclofenac peak concentration (Cmax) increased over time (0.28 [SD, 0.12], 0.38 [0.20], and 0.45 [0.4] mg/L on days 0, 1, and 8, respectively).",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.38,35123,DB01095,Fluvastatin
,7586933,peak concentration (Cmax),"Diclofenac peak concentration (Cmax) increased over time (0.28 [SD, 0.12], 0.38 [0.20], and 0.45 [0.4] mg/L on days 0, 1, and 8, respectively).",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.45,35124,DB01095,Fluvastatin
,7586933,urinary metabolic ratio (MR,"A time-dependent decrease in urinary metabolic ratio (MR, 4'-hydroxydiclofenac/diclofenac) was noted (1.07 [0.34], 0.90 [0.23] and 0.70 [0.18] on days 0, 1, and 8, respectively [p < 0.0001]) for the first 4 hours.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),,1.07,35125,DB01095,Fluvastatin
,7586933,urinary metabolic ratio (MR,"A time-dependent decrease in urinary metabolic ratio (MR, 4'-hydroxydiclofenac/diclofenac) was noted (1.07 [0.34], 0.90 [0.23] and 0.70 [0.18] on days 0, 1, and 8, respectively [p < 0.0001]) for the first 4 hours.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),,0.90,35126,DB01095,Fluvastatin
,7586933,urinary metabolic ratio (MR,"A time-dependent decrease in urinary metabolic ratio (MR, 4'-hydroxydiclofenac/diclofenac) was noted (1.07 [0.34], 0.90 [0.23] and 0.70 [0.18] on days 0, 1, and 8, respectively [p < 0.0001]) for the first 4 hours.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),,0.70,35127,DB01095,Fluvastatin
,7586933,Cmax,"Fluvastatin Cmax (0.18 [0.11] and 0.32 [0.1] mg/L on days 1 and 8, respectively) and area under the curve (0.28 [0.12] and 0.43 [0.15] hr.mg/L on days 1 and 8, respectively; p < 0.001) increased over time.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.18,35128,DB01095,Fluvastatin
,7586933,Cmax,"Fluvastatin Cmax (0.18 [0.11] and 0.32 [0.1] mg/L on days 1 and 8, respectively) and area under the curve (0.28 [0.12] and 0.43 [0.15] hr.mg/L on days 1 and 8, respectively; p < 0.001) increased over time.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[mg] / [l],0.32,35129,DB01095,Fluvastatin
,7586933,area under the curve,"Fluvastatin Cmax (0.18 [0.11] and 0.32 [0.1] mg/L on days 1 and 8, respectively) and area under the curve (0.28 [0.12] and 0.43 [0.15] hr.mg/L on days 1 and 8, respectively; p < 0.001) increased over time.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[h·mg] / [l],0.28,35130,DB01095,Fluvastatin
,7586933,area under the curve,"Fluvastatin Cmax (0.18 [0.11] and 0.32 [0.1] mg/L on days 1 and 8, respectively) and area under the curve (0.28 [0.12] and 0.43 [0.15] hr.mg/L on days 1 and 8, respectively; p < 0.001) increased over time.",In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586933/),[h·mg] / [l],0.43,35131,DB01095,Fluvastatin
,23036906,C(max),The mean C(max) from DBS sample (1121 ng/mL) was comparable to mean C(max) found in blood samples (1015 ng/mL) at 2h after oral dose of deferasirox.,Dried blood spot analysis of an iron chelator--deferasirox and its potential application to therapeutic drug monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23036906/),[ng] / [ml],1121,35339,DB01095,Fluvastatin
,23036906,C(max),The mean C(max) from DBS sample (1121 ng/mL) was comparable to mean C(max) found in blood samples (1015 ng/mL) at 2h after oral dose of deferasirox.,Dried blood spot analysis of an iron chelator--deferasirox and its potential application to therapeutic drug monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23036906/),[ng] / [ml],1015,35340,DB01095,Fluvastatin
,19782210,limit of detection,The assay limit of detection was 10 pg mL(-1) and the effective working range at relative standard deviations (RSD) of <or=5% was 20-1000 pg mL(-1).,Novel enzyme-linked immunosorbent assay for determination of fluvastatin in plasma at picogram level. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19782210/),[pg] / [ml],10,47505,DB01095,Fluvastatin
,19782210,Analytical recovery,Analytical recovery of FLV from spiked plasma was 97.1-102.7+/-2.85-6.25%.,Novel enzyme-linked immunosorbent assay for determination of fluvastatin in plasma at picogram level. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19782210/),%,97.1-102.7,47506,DB01095,Fluvastatin
,9797793,oral area under the serum concentration-time curve (AUC),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [min·ml],3607,52016,DB01095,Fluvastatin
,9797793,oral area under the serum concentration-time curve (AUC),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [min·ml],12886,52017,DB01095,Fluvastatin
,9797793,maximum serum concentration (Cmax),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],6,52018,DB01095,Fluvastatin
,9797793,maximum serum concentration (Cmax),Diltiazem significantly (P < .05) increased the oral area under the serum concentration-time curve (AUC) of lovastatin from 3607 +/- 1525 ng/ml/min (mean +/- SD) to 12886 +/- 6558 ng/ml/min and maximum serum concentration (Cmax) from 6 +/- 2 to 26 +/- 9 ng/ml but did not influence the elimination half-life.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],26,52019,DB01095,Fluvastatin
,9797793,steady-state serum concentrations,The average steady-state serum concentrations of diltiazem were not significantly different between the lovastatin (130 +/- 58 ng/ml) and pravastatin (110 +/- 30 ng/ml) study arms.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],130,52020,DB01095,Fluvastatin
,9797793,steady-state serum concentrations,The average steady-state serum concentrations of diltiazem were not significantly different between the lovastatin (130 +/- 58 ng/ml) and pravastatin (110 +/- 30 ng/ml) study arms.,The interaction of diltiazem with lovastatin and pravastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797793/),[ng] / [ml],110,52021,DB01095,Fluvastatin
,1640002,bioavailability,"Fluvastatin was rapidly and almost completely (greater than 90%) absorbed from the gastrointestinal tract, although the estimated bioavailability from the 2- and 10-mg doses was only 19 to 29% because of extensive first-pass metabolism.",Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1640002/),%,19 to 29,52495,DB01095,Fluvastatin
,1640002,terminal half-lives,"The terminal half-lives of fluvastatin and total radioactivity averaged 0.5 to 1 hour and 55 to 71 hours, respectively, whereas the total body clearance of fluvastatin was 0.97 L/hour/kg.",Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1640002/),h,0.5 to 1,52496,DB01095,Fluvastatin
,1640002,terminal half-lives,"The terminal half-lives of fluvastatin and total radioactivity averaged 0.5 to 1 hour and 55 to 71 hours, respectively, whereas the total body clearance of fluvastatin was 0.97 L/hour/kg.",Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1640002/),h,55 to 71,52497,DB01095,Fluvastatin
,1640002,total body clearance,"The terminal half-lives of fluvastatin and total radioactivity averaged 0.5 to 1 hour and 55 to 71 hours, respectively, whereas the total body clearance of fluvastatin was 0.97 L/hour/kg.",Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1640002/),[l] / [h·kg],0.97,52498,DB01095,Fluvastatin
higher,16480934,Recoveries,Recoveries were higher than 90% and the quantitation limit was 1.5 ng mL(-1) plasma for both enantiomers.,Chiral evaluation of fluvastatin in human plasma by high-performance liquid chromatography electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16480934/),%,90,69770,DB01095,Fluvastatin
,16480934,Recoveries,Recoveries were higher than 90% and the quantitation limit was 1.5 ng mL(-1) plasma for both enantiomers.,Chiral evaluation of fluvastatin in human plasma by high-performance liquid chromatography electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16480934/),[ng·plasma] / [ml],1.5,69771,DB01095,Fluvastatin
,16480934,AUC (-)/(+),"The data showed higher plasma concentrations of the (-)-3S,5R-fluvastatin enantiomer, with an AUC (-)/(+) of 1.84.",Chiral evaluation of fluvastatin in human plasma by high-performance liquid chromatography electrospray mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16480934/),,1.84,69772,DB01095,Fluvastatin
,16480934,Oral clearance values (CL/F),"Oral clearance values (CL/F) were 29.27 and 49.58 L/h, respectively, for the (-)-3S,5R- and (+)-3R,5S-fluvastatin enantiomers.",Chiral evaluation of fluvastatin in human plasma by high-performance liquid chromatography electrospray mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16480934/),[l] / [h],29.27,69773,DB01095,Fluvastatin
,16480934,Oral clearance values (CL/F),"Oral clearance values (CL/F) were 29.27 and 49.58 L/h, respectively, for the (-)-3S,5R- and (+)-3R,5S-fluvastatin enantiomers.",Chiral evaluation of fluvastatin in human plasma by high-performance liquid chromatography electrospray mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16480934/),[l] / [h],49.58,69774,DB01095,Fluvastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,47.0,75129,DB01095,Fluvastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,5.2,75130,DB01095,Fluvastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,15.0,75131,DB01095,Fluvastatin
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,3.3,75132,DB01095,Fluvastatin
,16625985,AUC0-12,"Treatment with fluvastatin XL, 80 mg for 7 days, had no significant effect on either the AUC0-12 (3,644 ng x h/ml in the absence of fluvastatin vs. 3,534 ng x h/ml in the presence of fluvastatin) or the Cmax of cyclosporine (983 ng/ml in the absence of fluvastatin vs. 945 ng/ml in the presence of fluvastatin).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[h·ng] / [ml],"3,644",76871,DB01095,Fluvastatin
,16625985,AUC0-12,"Treatment with fluvastatin XL, 80 mg for 7 days, had no significant effect on either the AUC0-12 (3,644 ng x h/ml in the absence of fluvastatin vs. 3,534 ng x h/ml in the presence of fluvastatin) or the Cmax of cyclosporine (983 ng/ml in the absence of fluvastatin vs. 945 ng/ml in the presence of fluvastatin).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[h·ng] / [ml],"3,534",76872,DB01095,Fluvastatin
,16625985,Cmax,"Treatment with fluvastatin XL, 80 mg for 7 days, had no significant effect on either the AUC0-12 (3,644 ng x h/ml in the absence of fluvastatin vs. 3,534 ng x h/ml in the presence of fluvastatin) or the Cmax of cyclosporine (983 ng/ml in the absence of fluvastatin vs. 945 ng/ml in the presence of fluvastatin).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[ng] / [ml],983,76873,DB01095,Fluvastatin
,16625985,Cmax,"Treatment with fluvastatin XL, 80 mg for 7 days, had no significant effect on either the AUC0-12 (3,644 ng x h/ml in the absence of fluvastatin vs. 3,534 ng x h/ml in the presence of fluvastatin) or the Cmax of cyclosporine (983 ng/ml in the absence of fluvastatin vs. 945 ng/ml in the presence of fluvastatin).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[ng] / [ml],945,76874,DB01095,Fluvastatin
,16625985,AUC0-24,"The AUC and Cmax for fluvastatin XL in the presence of cyclosporine (AUC0-24 1,192 ng.",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),ng,"1,192",76875,DB01095,Fluvastatin
,16625985,Cmax,"x h/ml, Cmax 271 ng/ml) were approximately 2-fold higher compared with historical data for fluvastatin XL alone in healthy volunteers (AUC0-24 630 ng x h/ml, Cmax 102 ng/ml) but lower than the historical data for fluvastatin IR, 40 mg b.i.d. alone in healthy volunteers (AUC0-24 1,340 ng x h/ml, Cmax 443 ng/ml).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[ng] / [ml],271,76876,DB01095,Fluvastatin
,16625985,AUC0-24,"x h/ml, Cmax 271 ng/ml) were approximately 2-fold higher compared with historical data for fluvastatin XL alone in healthy volunteers (AUC0-24 630 ng x h/ml, Cmax 102 ng/ml) but lower than the historical data for fluvastatin IR, 40 mg b.i.d. alone in healthy volunteers (AUC0-24 1,340 ng x h/ml, Cmax 443 ng/ml).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[h·ng] / [ml],630,76877,DB01095,Fluvastatin
,16625985,Cmax,"x h/ml, Cmax 271 ng/ml) were approximately 2-fold higher compared with historical data for fluvastatin XL alone in healthy volunteers (AUC0-24 630 ng x h/ml, Cmax 102 ng/ml) but lower than the historical data for fluvastatin IR, 40 mg b.i.d. alone in healthy volunteers (AUC0-24 1,340 ng x h/ml, Cmax 443 ng/ml).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[ng] / [ml],102,76878,DB01095,Fluvastatin
,16625985,AUC0-24,"x h/ml, Cmax 271 ng/ml) were approximately 2-fold higher compared with historical data for fluvastatin XL alone in healthy volunteers (AUC0-24 630 ng x h/ml, Cmax 102 ng/ml) but lower than the historical data for fluvastatin IR, 40 mg b.i.d. alone in healthy volunteers (AUC0-24 1,340 ng x h/ml, Cmax 443 ng/ml).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[h·ng] / [ml],"1,340",76879,DB01095,Fluvastatin
,16625985,Cmax,"x h/ml, Cmax 271 ng/ml) were approximately 2-fold higher compared with historical data for fluvastatin XL alone in healthy volunteers (AUC0-24 630 ng x h/ml, Cmax 102 ng/ml) but lower than the historical data for fluvastatin IR, 40 mg b.i.d. alone in healthy volunteers (AUC0-24 1,340 ng x h/ml, Cmax 443 ng/ml).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[ng] / [ml],443,76880,DB01095,Fluvastatin
,30033871,PDI,"The average particle size of SSMED-XDP was 154.30±1.10 nm, PDI was 0.311±0.03 and ZP was +19.57±1.34 mV after dilution.",Improvement of Anti-Hyperlipidemic Activity and Oral Bioavailability of Fluvastatin Via Solid Self-Microemulsifying Systems and Comparative with Liquisolid Formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30033871/),,0.311,79892,DB01095,Fluvastatin
,32373204,Km,"In vitro study demonstrated that when the concentration of fluvastatin was low (< 1 µmol/l), the uptake of fluvastatin in the HEK293-OATP1B1 with SLCO1B1 521TT (Km =0.18 µmol/l) was faster than that with SLCO1B1 521CC (Km =0.49 µmol/l), On the other hand, when concentration reached to higher level (> 1 µmol/l), transport velocity of fluvastatin by HEK293-OATP1B1 with SLCO1B1 521TT (Km = 11.4 µmol/l) and with SLCO1B1 521TCC (Km =15.1 µmol/l) tend to be the same.",The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32373204/),[μM] / [l],0.18,80018,DB01095,Fluvastatin
,32373204,Km,"In vitro study demonstrated that when the concentration of fluvastatin was low (< 1 µmol/l), the uptake of fluvastatin in the HEK293-OATP1B1 with SLCO1B1 521TT (Km =0.18 µmol/l) was faster than that with SLCO1B1 521CC (Km =0.49 µmol/l), On the other hand, when concentration reached to higher level (> 1 µmol/l), transport velocity of fluvastatin by HEK293-OATP1B1 with SLCO1B1 521TT (Km = 11.4 µmol/l) and with SLCO1B1 521TCC (Km =15.1 µmol/l) tend to be the same.",The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32373204/),[μM] / [l],0.49,80019,DB01095,Fluvastatin
,32373204,Km,"In vitro study demonstrated that when the concentration of fluvastatin was low (< 1 µmol/l), the uptake of fluvastatin in the HEK293-OATP1B1 with SLCO1B1 521TT (Km =0.18 µmol/l) was faster than that with SLCO1B1 521CC (Km =0.49 µmol/l), On the other hand, when concentration reached to higher level (> 1 µmol/l), transport velocity of fluvastatin by HEK293-OATP1B1 with SLCO1B1 521TT (Km = 11.4 µmol/l) and with SLCO1B1 521TCC (Km =15.1 µmol/l) tend to be the same.",The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32373204/),[μM] / [l],11.4,80020,DB01095,Fluvastatin
,32373204,Km,"In vitro study demonstrated that when the concentration of fluvastatin was low (< 1 µmol/l), the uptake of fluvastatin in the HEK293-OATP1B1 with SLCO1B1 521TT (Km =0.18 µmol/l) was faster than that with SLCO1B1 521CC (Km =0.49 µmol/l), On the other hand, when concentration reached to higher level (> 1 µmol/l), transport velocity of fluvastatin by HEK293-OATP1B1 with SLCO1B1 521TT (Km = 11.4 µmol/l) and with SLCO1B1 521TCC (Km =15.1 µmol/l) tend to be the same.",The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32373204/),[μM] / [l],15.1,80021,DB01095,Fluvastatin
,8941022,hepatic extraction,The mean hepatic extraction of fluvastatin was 67% after the jejunal perfusion and 73% after the intravenous infusion.,Jejunal permeability and hepatic extraction of fluvastatin in humans. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941022/),%,67,88754,DB01095,Fluvastatin
,8941022,hepatic extraction,The mean hepatic extraction of fluvastatin was 67% after the jejunal perfusion and 73% after the intravenous infusion.,Jejunal permeability and hepatic extraction of fluvastatin in humans. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941022/),%,73,88755,DB01095,Fluvastatin
,8941022,half-life,The half-life of fluvastatin was approximately 60 minutes after both administration routes.,Jejunal permeability and hepatic extraction of fluvastatin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941022/),min,60,88756,DB01095,Fluvastatin
,11509920,area under the serum concentration vs time curve (AUC),"After administration of 40 mg fluvastatin, the mean values of the area under the serum concentration vs time curve (AUC), the maximum serum drug concentration (C(max)), the time to reach C(max) (t(max)), and the serum elimination half-life time were 528.5 +/-358.8 ng/mL x h, 149.6 +/-56.0 ng/mL, 60.0 +/-30.0 minutes, and 108.0 +/-67.9 minutes, respectively.",Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11509920/),[ng] / [h·ml],528.5,89512,DB01095,Fluvastatin
,11509920,maximum serum drug concentration (C(max)),"After administration of 40 mg fluvastatin, the mean values of the area under the serum concentration vs time curve (AUC), the maximum serum drug concentration (C(max)), the time to reach C(max) (t(max)), and the serum elimination half-life time were 528.5 +/-358.8 ng/mL x h, 149.6 +/-56.0 ng/mL, 60.0 +/-30.0 minutes, and 108.0 +/-67.9 minutes, respectively.",Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11509920/),[ng] / [ml],149.6,89513,DB01095,Fluvastatin
,11509920,maximum serum drug concentration (C(max)),"After administration of 40 mg fluvastatin, the mean values of the area under the serum concentration vs time curve (AUC), the maximum serum drug concentration (C(max)), the time to reach C(max) (t(max)), and the serum elimination half-life time were 528.5 +/-358.8 ng/mL x h, 149.6 +/-56.0 ng/mL, 60.0 +/-30.0 minutes, and 108.0 +/-67.9 minutes, respectively.",Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11509920/),min,60.0,89514,DB01095,Fluvastatin
,11509920,time to reach C(max) (t(max)),"After administration of 40 mg fluvastatin, the mean values of the area under the serum concentration vs time curve (AUC), the maximum serum drug concentration (C(max)), the time to reach C(max) (t(max)), and the serum elimination half-life time were 528.5 +/-358.8 ng/mL x h, 149.6 +/-56.0 ng/mL, 60.0 +/-30.0 minutes, and 108.0 +/-67.9 minutes, respectively.",Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11509920/),[ng] / [ml],149.6,89515,DB01095,Fluvastatin
,11509920,time to reach C(max) (t(max)),"After administration of 40 mg fluvastatin, the mean values of the area under the serum concentration vs time curve (AUC), the maximum serum drug concentration (C(max)), the time to reach C(max) (t(max)), and the serum elimination half-life time were 528.5 +/-358.8 ng/mL x h, 149.6 +/-56.0 ng/mL, 60.0 +/-30.0 minutes, and 108.0 +/-67.9 minutes, respectively.",Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11509920/),min,60.0,89516,DB01095,Fluvastatin
,11509920,serum elimination half-life time,"After administration of 40 mg fluvastatin, the mean values of the area under the serum concentration vs time curve (AUC), the maximum serum drug concentration (C(max)), the time to reach C(max) (t(max)), and the serum elimination half-life time were 528.5 +/-358.8 ng/mL x h, 149.6 +/-56.0 ng/mL, 60.0 +/-30.0 minutes, and 108.0 +/-67.9 minutes, respectively.",Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11509920/),min,108.0,89517,DB01095,Fluvastatin
,22941809,AUC,"Heterozygous variant (C/A) carriers had higher AUC values compared to homozygous wild type (A/A) carriers (922.03±148.17 µg · h · L - 1 vs. 496.00±168.93 µg · h · L - 1, P=0.003092).","CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22941809/),-·1·h·l·μg,922.03,90372,DB01095,Fluvastatin
,22941809,AUC,"Heterozygous variant (C/A) carriers had higher AUC values compared to homozygous wild type (A/A) carriers (922.03±148.17 µg · h · L - 1 vs. 496.00±168.93 µg · h · L - 1, P=0.003092).","CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22941809/),-·1·h·l·μg,496.00,90373,DB01095,Fluvastatin
,22941809,elimination half-life (T 1/2),"The elimination half-life (T 1/2) values of fluvastatin were longer in MDR1 2677non-G carriers than in MDR1 2677G carriers (2.21±0.47 h vs. 1.25±0.62 h, P=0.02319), and also they were longer in MDR1 1236T-2677non-G-3435T carriers than in MDR1 1236C-2677G-3435C carriers (2.31±0.51 h vs. 1.32±0.62 h, P=0.03320).","CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22941809/),h,2.21,90374,DB01095,Fluvastatin
,22941809,elimination half-life (T 1/2),"The elimination half-life (T 1/2) values of fluvastatin were longer in MDR1 2677non-G carriers than in MDR1 2677G carriers (2.21±0.47 h vs. 1.25±0.62 h, P=0.02319), and also they were longer in MDR1 1236T-2677non-G-3435T carriers than in MDR1 1236C-2677G-3435C carriers (2.31±0.51 h vs. 1.32±0.62 h, P=0.03320).","CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22941809/),h,1.25,90375,DB01095,Fluvastatin
,22941809,elimination half-life (T 1/2),"The elimination half-life (T 1/2) values of fluvastatin were longer in MDR1 2677non-G carriers than in MDR1 2677G carriers (2.21±0.47 h vs. 1.25±0.62 h, P=0.02319), and also they were longer in MDR1 1236T-2677non-G-3435T carriers than in MDR1 1236C-2677G-3435C carriers (2.31±0.51 h vs. 1.32±0.62 h, P=0.03320).","CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22941809/),h,2.31,90376,DB01095,Fluvastatin
,22941809,elimination half-life (T 1/2),"The elimination half-life (T 1/2) values of fluvastatin were longer in MDR1 2677non-G carriers than in MDR1 2677G carriers (2.21±0.47 h vs. 1.25±0.62 h, P=0.02319), and also they were longer in MDR1 1236T-2677non-G-3435T carriers than in MDR1 1236C-2677G-3435C carriers (2.31±0.51 h vs. 1.32±0.62 h, P=0.03320).","CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22941809/),h,1.32,90377,DB01095,Fluvastatin
,22941809,C max,"Mutation gene T (TT+CT) carriers had higher C max values compared to homozygous wild type (C/C) carriers (688.54±142.67 µg · L - 1 vs. . 413.78±177.83 µg · L - 1, P=0.01448).","CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22941809/),-·1·l·μg,688.54,90378,DB01095,Fluvastatin
,22941809,C max,"Mutation gene T (TT+CT) carriers had higher C max values compared to homozygous wild type (C/C) carriers (688.54±142.67 µg · L - 1 vs. . 413.78±177.83 µg · L - 1, P=0.01448).","CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22941809/),-·1·l·μg,. 413.78,90379,DB01095,Fluvastatin
,16671968,absorption rate,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),1/[h],1,95456,DB01095,Fluvastatin
,16671968,elimination half-lives,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),h,14,95457,DB01095,Fluvastatin
,16671968,elimination half-lives,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),h,2,95458,DB01095,Fluvastatin
,16671968,elimination half-lives,"As no pharmacokinetic data were available, the absorption rate was fixed to 1/h and atorvastatin, simvastatin and fluvastatin elimination half-lives were fixed to 14, 2 and 2.5 h respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),h,2.5,95459,DB01095,Fluvastatin
,16671968,input rate (K(in)),"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),[g] / [d·l],0.14,95460,DB01095,Fluvastatin
,16671968,inhibition fraction of K(in),"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),,0.21,95461,DB01095,Fluvastatin
,16671968,dose,"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),mg,26,95462,DB01095,Fluvastatin
,16671968,L,"The following parameters were estimated: LDL input rate (K(in)) 0.14 +/- 0.015 g/L/day (mean +/- SD); inhibition fraction of K(in) (INH) 0.21 +/- 0.017; and dose producing 50% increase of LDL removal (D50), 26 +/- 7.8, 1.3 +/- 0.48 and 15 +/- 5.25 mg for atorvastatin, simvastatin and fluvastatin, respectively.",Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671968/),mg,26,95463,DB01095,Fluvastatin
,11907637,C(max.),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],869.4,99577,DB01095,Fluvastatin
,11907637,C(max.),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],211.9,99578,DB01095,Fluvastatin
,11907637,AUC(0h-24h),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],1948.8,99579,DB01095,Fluvastatin
,11907637,AUC(0h-24h),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],549.4,99580,DB01095,Fluvastatin
,11907637,CL,"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],33.3,99581,DB01095,Fluvastatin
,11907637,CL,"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],107.9,99582,DB01095,Fluvastatin
,11907637,C(max.),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],1530.4,99583,DB01095,Fluvastatin
,11907637,C(max.),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],254.7,99584,DB01095,Fluvastatin
,11907637,AUC(0h-24h),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],2615.3,99585,DB01095,Fluvastatin
,11907637,AUC(0h-24h),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],841.8,99586,DB01095,Fluvastatin
,11907637,CL,"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],21.4,99587,DB01095,Fluvastatin
,11907637,CL,"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],61.5,99588,DB01095,Fluvastatin
,19489169,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),min,30,100644,DB01095,Fluvastatin
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,40,100645,DB01095,Fluvastatin
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,60,100646,DB01095,Fluvastatin
,17703482,m,"The ion transitions recorded in multiple reaction monitoring mode were m/z 423 --> 101, 420 --> 290 and 410 --> 348 for pravastatin, pitavastatin and fluvastatin, respectively.","Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography-tandem mass spectrometry for pharmaceutical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17703482/),,423,114040,DB01095,Fluvastatin
,17703482,limit of detection,The limit of detection was 1 ng/mL for all analytes.,"Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography-tandem mass spectrometry for pharmaceutical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17703482/),[ng] / [ml],1,114041,DB01095,Fluvastatin
,17516719,steady-state AUC,"The coadministration of fluvastatin XL and amlodipine resulted in no significant changes in the steady-state AUC (469 vs 454 mug . h/L), C(max) (96 vs 89 mug/L), and CL/F (197 vs 232 L/h) of fluvastatin when compared with fluvastatin XL alone.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[h·μg] / [l],469,147595,DB01095,Fluvastatin
,17516719,steady-state AUC,"The coadministration of fluvastatin XL and amlodipine resulted in no significant changes in the steady-state AUC (469 vs 454 mug . h/L), C(max) (96 vs 89 mug/L), and CL/F (197 vs 232 L/h) of fluvastatin when compared with fluvastatin XL alone.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[h·μg] / [l],454,147596,DB01095,Fluvastatin
,17516719,C(max),"The coadministration of fluvastatin XL and amlodipine resulted in no significant changes in the steady-state AUC (469 vs 454 mug . h/L), C(max) (96 vs 89 mug/L), and CL/F (197 vs 232 L/h) of fluvastatin when compared with fluvastatin XL alone.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[μg] / [l],96,147597,DB01095,Fluvastatin
,17516719,C(max),"The coadministration of fluvastatin XL and amlodipine resulted in no significant changes in the steady-state AUC (469 vs 454 mug . h/L), C(max) (96 vs 89 mug/L), and CL/F (197 vs 232 L/h) of fluvastatin when compared with fluvastatin XL alone.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[μg] / [l],89,147598,DB01095,Fluvastatin
,17516719,CL/F,"The coadministration of fluvastatin XL and amlodipine resulted in no significant changes in the steady-state AUC (469 vs 454 mug . h/L), C(max) (96 vs 89 mug/L), and CL/F (197 vs 232 L/h) of fluvastatin when compared with fluvastatin XL alone.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[l] / [h],197,147599,DB01095,Fluvastatin
,17516719,CL/F,"The coadministration of fluvastatin XL and amlodipine resulted in no significant changes in the steady-state AUC (469 vs 454 mug . h/L), C(max) (96 vs 89 mug/L), and CL/F (197 vs 232 L/h) of fluvastatin when compared with fluvastatin XL alone.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[l] / [h],232,147600,DB01095,Fluvastatin
,17516719,steady-state AUC,"A similar comparison for amlodipine showed no significant difference in the steady-state AUC (132 vs 140 mug . h/L), C(max) (7.1 vs 7.5 mug/L) and CL/F (41 vs 40 L/h) of amlodipine.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[h·μg] / [l],132,147601,DB01095,Fluvastatin
,17516719,steady-state AUC,"A similar comparison for amlodipine showed no significant difference in the steady-state AUC (132 vs 140 mug . h/L), C(max) (7.1 vs 7.5 mug/L) and CL/F (41 vs 40 L/h) of amlodipine.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[h·μg] / [l],140,147602,DB01095,Fluvastatin
,17516719,C(max),"A similar comparison for amlodipine showed no significant difference in the steady-state AUC (132 vs 140 mug . h/L), C(max) (7.1 vs 7.5 mug/L) and CL/F (41 vs 40 L/h) of amlodipine.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[μg] / [l],7.1,147603,DB01095,Fluvastatin
,17516719,C(max),"A similar comparison for amlodipine showed no significant difference in the steady-state AUC (132 vs 140 mug . h/L), C(max) (7.1 vs 7.5 mug/L) and CL/F (41 vs 40 L/h) of amlodipine.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[μg] / [l],7.5,147604,DB01095,Fluvastatin
,17516719,CL/F,"A similar comparison for amlodipine showed no significant difference in the steady-state AUC (132 vs 140 mug . h/L), C(max) (7.1 vs 7.5 mug/L) and CL/F (41 vs 40 L/h) of amlodipine.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[l] / [h],41,147605,DB01095,Fluvastatin
,17516719,CL/F,"A similar comparison for amlodipine showed no significant difference in the steady-state AUC (132 vs 140 mug . h/L), C(max) (7.1 vs 7.5 mug/L) and CL/F (41 vs 40 L/h) of amlodipine.",Lack of Interaction between Modified-Release Fluvastatin and Amlodipine in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516719/),[l] / [h],40,147606,DB01095,Fluvastatin
,32004772,AUC0-24 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],72.00,162798,DB01095,Fluvastatin
,32004772,AUC0-24 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],65.57,162799,DB01095,Fluvastatin
,32004772,AUC0-6 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],15.33,162800,DB01095,Fluvastatin
,32004772,AUC0-6 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],8.15,162801,DB01095,Fluvastatin
,32004772,AUC0-24 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],75.79,162802,DB01095,Fluvastatin
,32004772,AUC0-24 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],32.88,162803,DB01095,Fluvastatin
,32004772,AUC0-6 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],17.07,162804,DB01095,Fluvastatin
,32004772,AUC0-6 h,"The administration of multiple doses of fluvastatin (n = 15) does not alter the values (geometric mean and 95 % CI) of AUC0-24 h of MVL [72.00 (57.49-90.18) vs 65.57 (51.73-83.12) ng∙h/mL], but reduces AUC0-6 h [15.33 (11.85-19.83) vs 8.15 (6.18-10.75) ng∙h/mL] by approximately 47 %, whereas single oral dose administration of atorvastatin (n = 15) reduces both AUC0-24 h [75.79 (65.10-88.24) vs 32.88 (27.05-39.96) ng∙h/mL] and AUC0-6 h [17.07 (13.87-21.01) vs 7.01 (5.99-8.22) ng∙h/mL] values by approximately 57 % and 59 %, respectively.",Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32004772/),[ng∙h] / [ml],7.01,162805,DB01095,Fluvastatin
,16026004,clearance,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[ml] / [kg·min],26,164283,DB01095,Fluvastatin
,16026004,clearance,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[ml] / [kg·min],12,164284,DB01095,Fluvastatin
,16026004,hepatic extraction,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),,30,164285,DB01095,Fluvastatin
,16026004,volume of distribution,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[l] / [kg],7.3,164286,DB01095,Fluvastatin
,16026004,volume of distribution,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[l] / [kg],2.1,164287,DB01095,Fluvastatin
>,16026004,permeability,The in vitro permeability for fluvastatin was high (>10 x 10(-6) cm/s).,Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[cm] / [s],10 x 10(-6),164288,DB01095,Fluvastatin
,16541405,linear dynamic,The assay exhibited a linear dynamic range of 2-500 ng/mL for fluvastatin in human plasma.,Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of fluvastatin in human plasma: validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16541405/),[ng] / [ml],2-500,173102,DB01095,Fluvastatin
,16541405,run time,A run time of 1.5 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of fluvastatin in human plasma: validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16541405/),min,1.5,173103,DB01095,Fluvastatin
,15462110,peak serum fluvastatin concentration (Cmax),The peak serum fluvastatin concentration (Cmax) was 141+/-67 microg/L and the mean AUC0-6 h was 341+/-149 microgh/L.,Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15462110/),[μg] / [l],141,179361,DB01095,Fluvastatin
,15462110,AUC0-6 h,The peak serum fluvastatin concentration (Cmax) was 141+/-67 microg/L and the mean AUC0-6 h was 341+/-149 microgh/L.,Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15462110/),[μgh] / [l],341,179362,DB01095,Fluvastatin
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB01095,Fluvastatin
,1600114,absorption,"In naive rabbits receiving a single oral dose (1 mg kg-1) of [3H] fluvastatin, absorption was rapid and amounted to c. 90 per cent compared with an intravenous reference dose.","Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600114/),%,c,190039,DB01095,Fluvastatin
,1600114,absorption,"In naive rabbits receiving a single oral dose (1 mg kg-1) of [3H] fluvastatin, absorption was rapid and amounted to c. 90 per cent compared with an intravenous reference dose.","Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600114/),%,90,190040,DB01095,Fluvastatin
,1600114,absolute bioavailability,"The drug was subject to considerable first-pass effect, its absolute bioavailability being 46 per cent.","Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600114/),%,46,190041,DB01095,Fluvastatin
,1600114,steady-state volume of distribution,The steady-state volume of distribution of fluvastatin was 0.29 +/- 0.04 l kg-1 while the total body clearance was 0.33 +/- 0.05 1 h-1 kg-1.,"Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600114/),[l] / [kg],0.29,190042,DB01095,Fluvastatin
,1600114,total body clearance,The steady-state volume of distribution of fluvastatin was 0.29 +/- 0.04 l kg-1 while the total body clearance was 0.33 +/- 0.05 1 h-1 kg-1.,"Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600114/),[1] / [h·kg],0.33,190043,DB01095,Fluvastatin
,9690949,Cmax,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[ng] / [ml],190,193159,DB01095,Fluvastatin
,9690949,Cmax,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[ng] / [ml],197,193160,DB01095,Fluvastatin
,9690949,total AUC,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[h·ng] / [ml],368,193161,DB01095,Fluvastatin
,9690949,total AUC,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[h·ng] / [ml],324,193162,DB01095,Fluvastatin
,9690949,"t1/2,z","However, the t1/2,z of fluvastatin was slightly prolonged by itraconazole (2.8 +/- 0.49 h vs 2.4 +/- 0.51 h; P < 0.05).",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,2.8,193163,DB01095,Fluvastatin
,9690949,"t1/2,z","However, the t1/2,z of fluvastatin was slightly prolonged by itraconazole (2.8 +/- 0.49 h vs 2.4 +/- 0.51 h; P < 0.05).",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,2.4,193164,DB01095,Fluvastatin
,9690949,"t1/2,z","The t1/2,z of lovastatin averaged 3.7 +/- 3.8 h and that of lovastatin acid 4.7 +/- 4.0 h during the itraconazole phase; these variables could not be determined in all subjects during the placebo phase.",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,3.7,193165,DB01095,Fluvastatin
,9690949,"t1/2,z","The t1/2,z of lovastatin averaged 3.7 +/- 3.8 h and that of lovastatin acid 4.7 +/- 4.0 h during the itraconazole phase; these variables could not be determined in all subjects during the placebo phase.",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,4.7,193166,DB01095,Fluvastatin
,11817313,Cmax,"Application of the method to a stereoselective study on the pharmacokinetics of fluvastatin administered as a single oral dose (Lescol, 20 mg) to a healthy volunteer revealed stereoselectivity, with the highest plasma concentrations being observed for the (-)-3S,5R isomer (Cmax 92.4 vs. 60.3 ng/ml, AUC(0-infinity) 133.3 vs. 97.4 ng h/ml, Cl/f 150.2 vs. 205.2 l h(-1) and Vd/f 4.4 vs. 6.0 l/kg).",Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11817313/),[ng] / [ml],92.4,193287,DB01095,Fluvastatin
,11817313,Cmax,"Application of the method to a stereoselective study on the pharmacokinetics of fluvastatin administered as a single oral dose (Lescol, 20 mg) to a healthy volunteer revealed stereoselectivity, with the highest plasma concentrations being observed for the (-)-3S,5R isomer (Cmax 92.4 vs. 60.3 ng/ml, AUC(0-infinity) 133.3 vs. 97.4 ng h/ml, Cl/f 150.2 vs. 205.2 l h(-1) and Vd/f 4.4 vs. 6.0 l/kg).",Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11817313/),[ng] / [ml],60.3,193288,DB01095,Fluvastatin
,11817313,AUC(0-infinity),"Application of the method to a stereoselective study on the pharmacokinetics of fluvastatin administered as a single oral dose (Lescol, 20 mg) to a healthy volunteer revealed stereoselectivity, with the highest plasma concentrations being observed for the (-)-3S,5R isomer (Cmax 92.4 vs. 60.3 ng/ml, AUC(0-infinity) 133.3 vs. 97.4 ng h/ml, Cl/f 150.2 vs. 205.2 l h(-1) and Vd/f 4.4 vs. 6.0 l/kg).",Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11817313/),[h·ng] / [ml],133.3,193289,DB01095,Fluvastatin
,11817313,AUC(0-infinity),"Application of the method to a stereoselective study on the pharmacokinetics of fluvastatin administered as a single oral dose (Lescol, 20 mg) to a healthy volunteer revealed stereoselectivity, with the highest plasma concentrations being observed for the (-)-3S,5R isomer (Cmax 92.4 vs. 60.3 ng/ml, AUC(0-infinity) 133.3 vs. 97.4 ng h/ml, Cl/f 150.2 vs. 205.2 l h(-1) and Vd/f 4.4 vs. 6.0 l/kg).",Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11817313/),[h·ng] / [ml],97.4,193290,DB01095,Fluvastatin
,11817313,Cl/f,"Application of the method to a stereoselective study on the pharmacokinetics of fluvastatin administered as a single oral dose (Lescol, 20 mg) to a healthy volunteer revealed stereoselectivity, with the highest plasma concentrations being observed for the (-)-3S,5R isomer (Cmax 92.4 vs. 60.3 ng/ml, AUC(0-infinity) 133.3 vs. 97.4 ng h/ml, Cl/f 150.2 vs. 205.2 l h(-1) and Vd/f 4.4 vs. 6.0 l/kg).",Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11817313/),[l] / [h],150.2,193291,DB01095,Fluvastatin
,11817313,Cl/f,"Application of the method to a stereoselective study on the pharmacokinetics of fluvastatin administered as a single oral dose (Lescol, 20 mg) to a healthy volunteer revealed stereoselectivity, with the highest plasma concentrations being observed for the (-)-3S,5R isomer (Cmax 92.4 vs. 60.3 ng/ml, AUC(0-infinity) 133.3 vs. 97.4 ng h/ml, Cl/f 150.2 vs. 205.2 l h(-1) and Vd/f 4.4 vs. 6.0 l/kg).",Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11817313/),[l] / [h],205.2,193292,DB01095,Fluvastatin
,11817313,Vd/f,"Application of the method to a stereoselective study on the pharmacokinetics of fluvastatin administered as a single oral dose (Lescol, 20 mg) to a healthy volunteer revealed stereoselectivity, with the highest plasma concentrations being observed for the (-)-3S,5R isomer (Cmax 92.4 vs. 60.3 ng/ml, AUC(0-infinity) 133.3 vs. 97.4 ng h/ml, Cl/f 150.2 vs. 205.2 l h(-1) and Vd/f 4.4 vs. 6.0 l/kg).",Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11817313/),[l] / [kg],4.4,193293,DB01095,Fluvastatin
,11817313,Vd/f,"Application of the method to a stereoselective study on the pharmacokinetics of fluvastatin administered as a single oral dose (Lescol, 20 mg) to a healthy volunteer revealed stereoselectivity, with the highest plasma concentrations being observed for the (-)-3S,5R isomer (Cmax 92.4 vs. 60.3 ng/ml, AUC(0-infinity) 133.3 vs. 97.4 ng h/ml, Cl/f 150.2 vs. 205.2 l h(-1) and Vd/f 4.4 vs. 6.0 l/kg).",Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11817313/),[l] / [kg],6.0,193294,DB01095,Fluvastatin
,24431079,IC50,The most potent CYP2C inhibitor identified in vitro was tamarixetin (IC50 = 1.4 μM).,Dietary flavonoids modulate CYP2C to improve drug oral bioavailability and their qualitative/quantitative structure-activity relationship. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24431079/),μM,1.4,197658,DB01095,Fluvastatin
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],80.3,199420,DB01095,Fluvastatin
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],78.5,199421,DB01095,Fluvastatin
,24521776,AUC0-24,"Mean rosuvastatin AUC0-24 was 157±61.7 ng*h/mL, approximately threefold higher than reported in the literature for nontransplants.",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·ng] / [ml],157,199422,DB01095,Fluvastatin
,12891229,area under the curve,"Mean (and SD) values for area under the curve of the active (+)-3R,5S-fluvastatin in carriers of the genotype CYP2C9*1/*1, *1/*3, and *3/*3 were 173 (85) micro g. L(-1).","Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891229/),[μg] / [l],173,208297,DB01095,Fluvastatin
,12891229,area under the curve,"The corresponding values for area under the curve of (-)-3S,5R-fluvastatin were 227 (133) micro g. L(-1).","Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891229/),[μg] / [l],227,208298,DB01095,Fluvastatin
,7787133,peak radioactivity concentrations (Cmax),"In the dog, peak radioactivity concentrations (Cmax) averaged 7260 ng equiv.",Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787133/),equiv·ng,7260,210837,DB01095,Fluvastatin
,7787133,time to peak (tmax),mL-1 and the mean time to peak (tmax) was approximately 9 h.,Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787133/),h,9,210838,DB01095,Fluvastatin
,7787133,radioact,"In the monkey, the mean radioactivity tmax values were approximately 5 and 13 h following the low and high doses, the respective Cmax values being 116 and 10,400 ng equiv.",Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787133/),h,5,210839,DB01095,Fluvastatin
,7787133,radioact,"In the monkey, the mean radioactivity tmax values were approximately 5 and 13 h following the low and high doses, the respective Cmax values being 116 and 10,400 ng equiv.",Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787133/),h,13,210840,DB01095,Fluvastatin
,7787133,tmax,"In the monkey, the mean radioactivity tmax values were approximately 5 and 13 h following the low and high doses, the respective Cmax values being 116 and 10,400 ng equiv.",Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787133/),h,5,210841,DB01095,Fluvastatin
,7787133,tmax,"In the monkey, the mean radioactivity tmax values were approximately 5 and 13 h following the low and high doses, the respective Cmax values being 116 and 10,400 ng equiv.",Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787133/),h,13,210842,DB01095,Fluvastatin
,7787133,Cmax,"In the monkey, the mean radioactivity tmax values were approximately 5 and 13 h following the low and high doses, the respective Cmax values being 116 and 10,400 ng equiv.",Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787133/),equiv·ng,116,210843,DB01095,Fluvastatin
,7787133,Cmax,"In the monkey, the mean radioactivity tmax values were approximately 5 and 13 h following the low and high doses, the respective Cmax values being 116 and 10,400 ng equiv.",Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787133/),equiv·ng,"10,400",210844,DB01095,Fluvastatin
,7787133,AUC ratio,"The AUC ratio of unchanged fluvastatin versus total radioactivity was approximately 63% in the dog, and 9% and 13% for the low and high doses, respectively in the monkey.",Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787133/),%,63,210845,DB01095,Fluvastatin
,7787133,AUC ratio,"The AUC ratio of unchanged fluvastatin versus total radioactivity was approximately 63% in the dog, and 9% and 13% for the low and high doses, respectively in the monkey.",Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787133/),%,9,210846,DB01095,Fluvastatin
,7787133,AUC ratio,"The AUC ratio of unchanged fluvastatin versus total radioactivity was approximately 63% in the dog, and 9% and 13% for the low and high doses, respectively in the monkey.",Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787133/),%,13,210847,DB01095,Fluvastatin
,2207302,bio,"Only at high doses far exceeding the intended human daily dose of ca 0.6 mg kg-1 did fluvastatin bioavailability approach unity, apparently due to saturation of the first-pass effect.","Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207302/),,unity,215989,DB01095,Fluvastatin
,2207302,half-life,The half-life of intact fluvastatin ranged from 1-2h in the monkey to 4-7h in the dog.,"Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207302/),h,1-2,215990,DB01095,Fluvastatin
,2207302,half-life,The half-life of intact fluvastatin ranged from 1-2h in the monkey to 4-7h in the dog.,"Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207302/),h,4-7,215991,DB01095,Fluvastatin
,10984808,clearance,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [h·kg],0.407,223254,DB01095,Fluvastatin
,10984808,volume of distribution,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [kg],4.0,223255,DB01095,Fluvastatin
,10984808,bioavailability,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),%,31,223256,DB01095,Fluvastatin
,10984808,half-life,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),h,10.6,223257,DB01095,Fluvastatin
,8297546,plasma half-life,"Systemic exposure is limited because of extensive sequestration by the liver and/or first-pass metabolism, a plasma half-life of approximately 30 min, no circulating active metabolites, and no accumulation of drug during chronic dosing.",Pharmacokinetics of fluvastatin and specific drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8297546/),min,30,232734,DB01095,Fluvastatin
,15660968,elimination half-lives,"Lovastatin, pravastatin and simvastatin are derived from fungal metabolites and have elimination half-lives of 1-3 h.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1-3,238379,DB01095,Fluvastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,1,238380,DB01095,Fluvastatin
,15660968,elimination half-lives,"Atorvastatin, cerivastatin (withdrawn from clinical use in 2001), fluvastatin, pitavastatin and rosuvastatin are fully synthetic compounds, with elimination half-lives ranging from 1 h for fluvastatin to 19 h for rosuvastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),h,19,238381,DB01095,Fluvastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,5,238382,DB01095,Fluvastatin
,15660968,bioavailability,"The bioavailability of the statins differs greatly, from 5% for lovastatin and simvastatin to 60% or greater for cerivastatin and pitavastatin.","Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15660968/),%,60,238383,DB01095,Fluvastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],1.44,256262,DB01095,Fluvastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],30.6,256263,DB01095,Fluvastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],12.7,256264,DB01095,Fluvastatin
,19875501,uptake clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·liver·min],62.9,256265,DB01095,Fluvastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],0.84-1.2,256266,DB01095,Fluvastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],14-35,256267,DB01095,Fluvastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],11-19,256268,DB01095,Fluvastatin
,19875501,intrinsic hepatic clearance,"In vivo uptake clearance of the statins in humans (pravastatin, 1.44; pitavastatin, 30.6; atorvastatin, 12.7; and fluvastatin, 62.9 ml/min/g liver), which was obtained by multiplying in vitro uptake clearance determined in cryopreserved human hepatocytes by rat scaling factors, was within the range of overall in vivo intrinsic hepatic clearance (pravastatin, 0.84-1.2; pitavastatin, 14-35; atorvastatin, 11-19; and fluvastatin, 123-185 ml/min/g liver), whereas the intrinsic metabolic clearance of atorvastatin and fluvastatin was considerably low compared with their intrinsic hepatic clearance.",Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19875501/),[ml] / [g·min],123-185,256269,DB01095,Fluvastatin
,8729584,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),min,30,257876,DB01095,Fluvastatin
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,40,257877,DB01095,Fluvastatin
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,60,257878,DB01095,Fluvastatin
,31736366,permeation characteristics,"The optimum SNVs were nano-scaled spherical vesicles (201.54 ± 9.16 nm), having reasonable entrapment efficiency (71.28 ± 2.05%), appropriate release over 8 h (89.45 ± 3.64%) and adequate permeation characteristics across the skin (402.55 ± 27.48 µg/cm2).",Transdermal delivery of fluvastatin sodium via tailored spanlastic nanovesicles: mitigated Freund's adjuvant-induced rheumatoid arthritis in rats through suppressing p38 MAPK signaling pathway. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31736366/),[μg] / [cm2],402.55,272431,DB01095,Fluvastatin
